Covaxin
Covaxin overall 77.8% effective against COVID-19, claims Bharat Biotech
New Delhi/IBNS: Hyderabad-based biotechnology company Bharat Biotech has claimed its anti-COVID-19 vaccine, Covaxin, is 77.8% effective against the deadly virus.
Bharat Biotech made the claim in the phase three clinical trial data of the vaccine.
The company has further claimed Covaxin is 93.4% effective against severe symptomatic COVID-19 cases, 63.6% against asymptomatic COVID-19 cases and 65.2% against the Delta variant.
COVAXIN® Proven SAFE in India's Largest Efficacy Trial. Final Phase-3 Pre-Print Data Published on https://t.co/JJh9n3aB6V pic.twitter.com/AhnEg56vFN
— BharatBiotech (@BharatBiotech) July 2, 2021
Bharat Biotech co-founder Suchitra Ella tweeted, "We are proud to put India on the global map with scientific conviction,competence & commitment. #Covaxin scores #10 world class publications endorsing Innovation, clinical research,data,safety, efficacy. Thanq collaborators & Positive BB teamwork enduring a pandemic."
We are proud to put India on the global map with scientific conviction,competence & commitment. #Covaxin scores #10 world class publications endorsing Innovation, clinical research,data,safety, efficacy. Thanq collaborators & Positive BB teamwork enduring a pandemic 😇👏🏼👍🏼💉🇮🇳🙏🏼 https://t.co/c5f43WOAbQ
— suchitra ella (@SuchitraElla) July 2, 2021
At present four anti-COVID-19 vaccines including Covaxin have been permitted by the central government to be used in the vaccination drive.
Apart from Covaxin, three other vaccines are AstraZeneca's Indian version Covishield, Russia's Sputnik and US-made Moderna.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
